Evaluation of comparative bioavailability and bioequivalence analysis of terazosin hydrochloride
Abstract
Terazosin hydrochloride is a selective α₁-adrenergic receptor antagonist used to treat high blood pressure and benign prostatic hyperplasia. Due to interest by patients, prescribers, and payers for cost-effective and therapeutically equivalent generic formulations, the evaluation of bioavailability and Bioequivalence (BE) has been a significant focus area for regulatory authorities and pharmaceutical companies. Regulatory authorities, including the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established guidelines related to the requirements for BE studies, as well as requiring the use of validated bioanalytical methods to quantify drug concentrations in biological matrices. BE studies focus on pharmacokinetic parameters such as the maximum plasma concentration (Cmax), time to Cmax (Tmax), and area under the curve (AUC) from the plasma concentration vs. time curve, which gives an estimate of the rate and extent of drug absorption. This article discusses current regulatory frameworks and important considerations in the design and conduct of BE studies recently provided by the FDA and EMA (e.g., validated bioanalytical methods and pharmacokinetic parameters such as Tmax, Cmax and AUC). The extent to which the industry adheres to BE study design and conduct regulations, as well as the issues around studying population, dosage form and statistical analysis of the results, will also be explored. Discussion will also include…
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.